Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent?

Microbes and Infection

Volumn 10, Issue 9, 2008, Pages 953-959

  Alexander, James ^a   McFarlane, Emma ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

IL 13; IL 4; Leishmania; Th1; Th2

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; KINETOPLAST MEMBRANE PROTEIN PROTEIN 11 DNA VACCINE; STIBOCAPTATE; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA ALBICANS; CRYPTOSPORIDIUM PARVUM; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LISTERIA MONOCYTOGENES; NONHUMAN; PRIORITY JOURNAL; TH2 CELL; TOXOPLASMA GONDII; VISCERAL LEISHMANIASIS;

ANIMALS; CYTOKINES; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; INTRACELLULAR SPACE; LEISHMANIA; LEISHMANIASIS; TH1 CELLS; TH2 CELLS;

PROTOZOA;

EID: 53449090505     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.07.038     Document Type: Article

References (71)

1. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136 (1986) 2348-2357
2. Bettelli E., Oukka M., and Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8 (2007) 345-350
3. Suzuki Y., Yang Q., Yang S., Nguyen N., Lim S., Liesenfeld O., Kojima T., and Remington J.S. IL-4 is protective against development of toxoplasmic encephalitis. J. Immunol. 157 (1996) 2564-2569
4. Flesch I.E., Wandersee A., and Kaufmann S.H. Effects of IL-13 on murine listeriosis. Int. Immunol. 9 (1997) 467-474
5. + T helper type 1 responses to Candida albicans. J. Exp. Med. 187 (1998) 307-317
6. McDonald S.A., O'Grady J.E., Bajaj-Elliott M., Notley C.A., Alexander J., Brombacher F., and McDonald V. Protection against the early acute phase of cryptosporidium parvum infection conferred by Interleukin-4-induced expression of T Helper 1 cytokines. J. Infect. Dis. 190 (2004) 1019-1025
7. Biedermann T., Zimmermann S., Himmelrich H., Gumy A., Egeter O., Sakrauski A.K., Seegmüller I., Voigt H., Launois P., Levine A.D., Wagner H., Heeg K., Louis J.A., and Rocken M. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2 (2001) 1054-1060
8. Alexander J., Carter K.C., Al-Fasi N., Satoskar A., and Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30 (2000) 2935-2943
9. Stager S., Alexander J., Carter K.C., Brombacher F., and Kaye P.M. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71 (2003) 4804-4807
10. + T-cell responses. Nat. Med. 9 (2003) 1287-1292
11. -/- mice. Infect. Immun. 74 (2006) 2487-2490
12. Ramanathan S., de Kosak Y., Saoudi A., Goureau O., Van der Meide P.H., Druet P., and Bellon B. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J. Immunol. 157 (1996) 2209-2215
13. Fort M.M., Lesley R., Davidson N.J., Menon S., Brombacher F., Leach M.W., and Rennick D.M. IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J. Immunol. 166 (2001) 2793-2800
14. Hochrein H., O'Keefe M., Luft T., Vandenabeele S., Grumont R.J., Maraskovsky E., and Shortman K. Interleukin (IL-4) is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J. Exp. Med. 192 (2000) 823-833
15. Noble A., and Kemeny D.M. Interleukin-4 enhances interferon-γ synthesis but inhibits development of interferon-γ-producing cells. Immunology 85 (1995) 357-363
16. Lean I.-S., McDonald S.A., Bajaj-Elliott M., Pollok R.C.G., Farthing M.J.G., and McDonald V. Interleukin-4 and transforming growth factor-beta have opposing regulatory effects on gamma interferon-mediated inhibition of Cryptosporidium parvum reproduction. Infect. Immun. 71 (2003) 4580-4585
17. Bogdan C., Stenger S., Rollinghoff M., and Solbach W. Cytokine interactions in experimental cutaneous leishmaniasis. Interleukin 4 synergizes with interferon-gamma to activate murine macrophages for killing of Leishmania major amastigotes. Eur. J. Immunol. 21 (1993) 327-333
18. McMahon-Pratt D., and Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?. Immunol. Rev. 201 (2004) 206-224
19. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., and Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169 (1989) 59-72
20. + T cells which are NK1.1. Eur. J. Immunol. 25 (1995) 3298-3007
21. Scott P., Eaton A., Gause W.C., di Zhou X., and Hondowicz B. Early IL-4 production does not predict susceptibility to Leishmania major. Exp. Parasitol. 84 (1996) 178-187
22. Kopf M., Brombacher F., Kohler G., Kienzle G., Widmann K.H., Lefrang K., Humborg B., Lederman B., and Solbach W. IL-4 deficient mice resist infection with Leishmania major. J. Exp. Med. 184 (1996) 1127-1136
23. Noben-Trauth N., Kropf P., and Muller I. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271 (1996) 987-990
24. Mohrs M., Holscher C., and Brombacher F. Interleukin-4 receptor alpha deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Infect. Immun. 68 (2000) 1773-1780
25. Noben-Trauth N., Paul W.E., and Sacks D.L. IL-4- and IL-4 receptor deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162 (1999) 6132-6140
26. Matthews D.J., Emson C.L., McKenzie G.J., Jolin H.E., Blackwell J.M., and McKenzie A.N. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164 (2000) 1458-1462
27. Mohrs M., Ledermann B., Kohler G., Dorfmuller A., Gessner A., and Brombacher F. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 162 (1999) 7302-7308
28. Noben-Trauth N., Lira R., Nagase H., Paul W.E., and Sacks D.L. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170 (2003) 5152-5158
29. Kane M.M., and Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166 (2001) 1141-1147
30. Sacks D., and Anderson C. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol. Rev. 201 (2004) 225-238
31. Anderson C.F., Oukka M., Kuchroo V.J., and Sacks D.L. CD4+CD25-Foxp3-Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204 (2007) 285-297
32. + T cells during initiation of infection. J. Exp. Med. 179 (1994) 447-456
33. + T cells resulting in a state of unresponsiveness to IL-12. J. Immunol. 161 (1998) 6156-6163
34. Jones D., Elloso M.M., Showe L., Williams D., Trinchieri G., and Scott P. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect. Immun. 66 (1998) 3818-3824
35. Von Stebut E., Ehrchen J.M., Belkaid Y., Kostka S.L., Molle K., Knop J., Sunderkotter C., and Udey M.C. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major susceptible BALB/c mice. J. Exp. Med. 198 (2003) 191-199
36. Eriksson U., Kurrer M.O., Sonderegger I., Iezzi G., Tafuri A., Hunziker L., Suzuki S., Bachmaier K., Bingisser R.M., Penninger J.M., and Kopf M. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J. Exp. Med. 197 (2003) 323-331
37. Oriss T.B., McCarthy S.A., Morel B.F., Campana M.A., and Morel P.A. Cross-regulation between T helper cell (Th)1 and Th2: inhibition of Th2 proliferation by IFN-γ involves interference with IL-1. J. Immunol. 158 (1997) 3666-3672
38. Nishikomori R., Gurunathan S., Nishikomori K., and Strober W. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling. J. Immunol. 166 (2001) 6776-6783
39. + T cell-intrinsic mechanism. J. Exp. Med. 188 (1998) 2289-2299
40. Maldonado R.A., Irvine D.J., Schreiber R., and Glimcher L.H. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 431 (2004) 527-532
41. Radwanska M., Cutler A.J., Hoving J.C., Magez S., Holscher C., Bohms A., Arendse B., Kirsch R., Hunig T., Alexander J., Kaye P.M., and Brombacher F. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog. 3 5 (2007) e68
42. Holscher C., Arendse B., Schwegmann A., Myburgh E., and Brombacher F. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in non-healing BALB/c mice. J. Immunol. 176 (2006) 1115-1121
43. Gicheru M.M., Olobo J.O., Anjili C.O., Modabber F., and Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69 (2001) 245-251
44. Kenny R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., and Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163 (1999) 4481-4488
45. Melby P.C., Ogden G.B., Flores H.A., Zhao W., Geldmacher C., Biediger N.M., Ahuja S.K., Uranga J., and Melendez M. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68 (2000) 5595-5602
46. Engwerda C.R., Murphy M.L., Cotterell S.L., Smelt S.C., and Kaye P.M. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28 (1998) 669-680
47. Murray H.W., Hariprashad J., and Coffman R.L. Behaviour of visceral Leishmania donovani in an experimentally induced T helper associated response model. J. Exp. Med. 185 (1997) 867-874
48. Murray H.W., and Nathan C.F. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189 (1999) 741-746
49. Kaye P.M., Curry A.J., and Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146 (1991) 2763-2770
50. Kemp M., Kurtzhals J.A., Bendtzen K., Poulsen L.K., Hansen M.B., Koech D.K., Kharazmi A., and Theander T.G. Leishmania donovani reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61 (1993) 1069-1073
51. Kemp K. Cytokine-producing T cell subsets in human leishmaniasis. Arch. Immunol. Ther. Exp. 48 (2000) 173-177
52. Karp C.L., el-Safi S.H., Wynn T.A., Satti M.M., Kordofani A.M., Hashim F.A., Hag-Ali M., Neva F.A., Nutman T.B., and Sacks D.L. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest 91 (1993) 1644-1648
53. Murphy M.L., Cotterell S.E.J., Gorak P.M.A., Engwerda C.R., and Kaye P.M. Blockade of CTLA4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 166 (1998) 4153-4160
54. Murphy M.L., Wille U., Villegas E.N., Hunter C.A., and Farrell J.P. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31 (2001) 848-856
55. Bodas M., Jain N., Awasthi A., Martin S., Kumar R., Loka P., Dandekar D., Mitra D., and Saha B. Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy. J. Immunol. 177 (2006) 4636-4643
56. Satoskar A., Bluethmann H., and Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63 (1995) 4894-4899
57. Murray H.W., Montelibano C., Peterson R., and Sypek J.P. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182 (2000) 1497-1502
58. Murray H.W., Oca M.J., Granger A.M., and Schreiber R.D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. J. Clin. Invest 83 (1989) 1253-1257
59. Basu R., Bhaumik S., Halder A.K., Naskar K., De T., Dana S.K., Walden P., and Roy S. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect. Immun. 75 (2007) 5956-5966
60. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174 (2005) 160-171
61. Mottram J.C., Coombs G.H., and Alexander J. Cysteine peptidases as virulence factors of Leishmania. Curr. Opin. Microbiol. 7 (2004) 375-381
62. Buxbaum L.U., Uzonna J.E., Goldschmidt M.H., and Scott P. Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent. Eur. J. Immun. 32 (2002) 3206-3615
63. Satoskar A., and Alexander J. Sex determined susceptibility and differential IFN-γ and TNF-α in mRNA expression in DBA/2 mice infected with Leishmania mexicana. Immunology 84 (1995) 1-4
64. Satoskar A., Brombacher F., Dai W.J., McInnes I., Liew F.Y., Alexander J., and Walker W. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis. J. Immunol. 159 (1997) 5005-5013
65. Mohrs K., Wakil A.E., Killeen N., Locksley R.M., and Mohrs M. A two-step process for cytokine production revealed by IL-4 dual-reporter mice. Immunity 23 (2005) 419-429
66. Alexander J., Brombacher F., McGachy H.A., McKenzie A.N., Walker W., and Carter K.C. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32 (2002) 2923-2933
67. Jones D.E., Buxbaum L.U., and Scott P. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J. Immunol. 165 (2000) 364-372
68. Jones D.E., Ackermann M.R., Wille U., Hunter C.A., and Scott P. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70 (2002) 2151-2058
69. Padigel U.M., Alexander J., and Farrell J.P. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171 (2003) 3705-3710
70. Buxbaum L.U., and Scott P. Interleukin 10 and Fc gamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73 (2005) 101-108
71. Hsu A.C., and Scott P. Leishmania mexicana infection induces impaired lymph node expansion and Th1 cell differentiation despite normal T cell proliferation. J. Immunol. 179 (2007) 8200-8207